Serum interleukin-6 levels in response to biologic treatment in patients with psoriasis

Muramatsu, Soshi; Kubo, Ryoji; Nishida, Emi; Akimichi, Morita

doi:10.3109/14397595.2016.1174328

Cited by 37 publications

(28 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our study shows that IL-6 might be related to dyslipidemia in psoriasis because patients with abnormal blood lipids had higher IL-6 concentrations than patients with normal blood lipids. In previous studies, serum IL-6 concentrations were increased in patients with psoriasis and correlated with disease activity assessed with the PASI and DAS28-CRP [15,17]. Similarly, we found that IL-6 concentrations were greater in patients with concurrent PsA, which is clinically more severe than plaque psoriasis.…”

Section: Discussionsupporting

confidence: 81%

“…Thus, serum IL-6 concentrations may be used to assess psoriasis severity and response to treatment [11]. Based on a study among 182 patients with psoriasis who received biological treatments, Muramatsu et al suggested that serum concentrations of IL-6 might be particularly valuable for monitoring disease activity in patients who receive infliximab or adalimumab [15]. Moreover, the IL-6 signaling pathway is a potential treatment target in psoriasis [20,21].…”

Section: Discussionmentioning

confidence: 99%

“…the appearance of skin lesions after skin trauma [3,4]. Most previous studies have reported increased serum IL-6 concentrations in patients with psoriasis, particularly in those with active disease [3,[6][7][8][9][10][11][12][13][14][15]. The concentration of IL-6 in serum might be related to the severity of both psoriatic skin lesions and joint involvement.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Serum concentration of interleukin 6 is related to inflammation and dyslipidemia in patients with psoriasis

Pietrzak¹,

Chabros²,

Grywalska³

et al. 2020

pdia

View full text Add to dashboard Cite

Introduction: Patients with psoriasis and psoriatic arthritis (PsA) have metabolic disturbances, which may be due to chronic inflammation. Aim: Because interleukin-6 (IL-6) regulates both metabolic and inflammatory processes, we evaluated IL-6 as a potential marker of inflammation and metabolic disturbances in psoriasis. Material and methods: This study involved 93 patients with psoriasis, including 31 patients with concurrent PsA. We investigated whether serum markers of lipid metabolism and inflammation, including IL-6, were related to each other and to disease activity. Results: We found that concurrent PsA was associated with higher serum concentrations of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and IL-6. In patients with psoriasis alone, the IL-6 serum concentration correlated positively with the concentrations of TC and LDL-c and with erythrocyte sedimentation rates (ESRs). Moreover, IL-6 concentrations tended to correlate positively with the percentage of the body area affected by psoriatic lesions. Among all patients, those with normal blood lipids had lower ESRs and IL-6 concentrations than patients with abnormal blood lipids. A logistic regression model showed that PsA, Psoriasis Area Severity Index (PASI), and ESR were significant predictors of the serum IL-6 concentration. Conclusions: Interleukin-6 may be an indicator of inflammatory activity in psoriasis. Moreover, IL-6 may be related to lipid abnormalities in patients with this disease.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum concentration of interleukin 6 is related to inflammation and dyslipidemia in patients with psoriasis

Pietrzak¹,

Chabros²,

Grywalska³

et al. 2020

pdia

View full text Add to dashboard Cite

show abstract

“…It also acts as a myokine and is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance [23]. Genetic polymorphism of IL6 has been shown to be significantly associated with a form of psoriatic arthritis [24], and serum IL6 is considered as a biomarker for assessing disease activity in patients with psoriasis, as well as for predicting responsiveness of joint symptoms to biologic treatment [25].…”

Section: Prediction Scores Of Target-indication Pairs Under Clinical mentioning

confidence: 99%

Predicting clinically promising therapeutic hypotheses using tensor factorization

Yao

Hurle

Nelson

et al. 2018

Preprint

View full text Add to dashboard Cite

Determining which target to pursue is a challenging and error-prone first step in developing a therapeutic treatment for a disease, where missteps are potentially very costly given the long-time frames and high expenses of drug development. We identified examples of successes and failures of target-indication pairs in clinical trials across 875 targets and 574 disease indications to build a goldstandard data set of 6,140 known clinical outcomes. We used information from Open Targets and others databases that covered 17 different sources of evidence for target-indication association and represented the data as a matrix of 21,437×2,211×17 with over two million non-null values. We designed and executed three benchmarking strategies to examine the performance of multiple machine learning models: Logistic Regression, Elasticnet, Random Forest, Tensor Factorization and Gradient Boosting Machine. With ten-fold cross validation, tensor factorization achieved AUROC=0.82±0.02 and AUPRC=0.71±0.03. Across multiple validation schemes, this was comparable or better than other methods. Tensor factorization is a general form of matrix factorization that has been successfully exploited in recommendation systems that suggest items to users based on their existing preference on a small number of items. Our application, using Bayesian probabilistic modelling, extends the capacity of matrix factorization to model multiple relationships between and among targets and indications. We use the model to show that our predicted probabilities of success correlate with clinical phases, and within clinical phase we can predict which trials are most likely to succeed.

show abstract

“…Além do TNF-α, a IL-6 é considerada na atividade da psoríase, sendo que os níveis sanguíneos se correlacionam com escores da psoríase vulgar e o tratamento, que visa diminuir os níveis de IL-6, e pode produzir melhoras na doença (MUrAMATSU et al, 2016). Com relação às interleucinas, o laser de baixa potência também tem se mostrado atuante, tanto com diminuição daquelas consideradas pró-inflamatórias, como a IL-1α (OLIVEIRA et al, 2017), IL-6 (ALVES et al, 2016), IL-8 (CARVALHO et al, 2017), quanto com aumento das antiinflamatórias, como IL-10 (CARVALHO et al, 2017), IL-4, IL-13 (SONG et al, 2017).…”

Section: Resultsunclassified

Efeitos Do Laser De Baixa Potência Na Remissão De Feridas Causadas Pela Psoríase Vulgar

et al. 2017

View full text Add to dashboard Cite

RESUMO:Psoríase é um tipo de dermatose crônica de evolução variada representada por lesões eritemato-escamosas e alterações proliferativas e inflamatórias da pele, podendo ocorrer em todas as idades e gêneros. Este estudo teve como objetivo avaliar os efeitos do laser de baixa potência, 660 nm, na remissão e melhora do aspecto de feridas causadas pela psoríase em placa. Este é um estudo longitudinal, experimental, de caráter quali e quantitativo. A amostra foi composta por indivíduos com psoríase em placas em período exacerbado e que não estavam passando por nenhum outro tipo de tratamento. A amostra foi dividida em Grupo Controle (GC), que não foi submetido ao tratamento; e Grupo Tratamento (GT) que foi submetido ao tratamento com laser de baixa potência, 660nm. Nos resultados obtidos para GC, a evolução entre as avaliações da área das feridas foi de 83,80±11,96 cm² para 82,90±12,01 cm² (p>0,05), para GT, foi de 74,25±9,61 cm² para 56,25±24,36 cm (p=0,014); a análise qualitativa ratificou que a terapia com laser de baixa potência pode melhorar os aspectos físicos das feridas causadas pela psoríase em placa, bem como diminuir sua área total. PALAVRAS-CHAVE:Psoríase; Terapia a laser; Úlcera cutânea. EFFECTS OF LOW-GRADE LASER IN WOUNDS CAUSED BY COMMON PSORIASISABSTRACT: Psoriasis, a chronic skin disease with different kinds of evolution, is characterized by erythemate-squamous lesions and proliferate and inflammatory changes on the skin, occurring at all ages and in males and females alike.

show abstract

Serum interleukin-6 levels in response to biologic treatment in patients with psoriasis

Abstract: Serum IL-6 level may be a useful biomarker for assessing disease activity in patients with psoriasis and for predicting responsiveness of joint symptoms to biologic treatment.

Cited by 37 publications

References 20 publications

Serum concentration of interleukin 6 is related to inflammation and dyslipidemia in patients with psoriasis

Serum concentration of interleukin 6 is related to inflammation and dyslipidemia in patients with psoriasis

Predicting clinically promising therapeutic hypotheses using tensor factorization

Efeitos Do Laser De Baixa Potência Na Remissão De Feridas Causadas Pela Psoríase Vulgar

Contact Info

Product

Resources

About